When the researchers mimicked a systemic infection in mice, animals deficient in Del - 1 were slower to begin
making myeloid cells again compared to those with normal Del - 1 levels.
Not exact matches
That's how Charles Sawyers, a 2009 Lasker Award winner and chair of human oncology and pathogenesis at Memorial Sloan - Kettering Cancer Center in New York City,
made the connection with Bristol Myers Squibb (BMS) that led to second - generation treatments for chronic
myeloid leukemia (CML).
Deshpande aims to
make a big impact with this work — he's first focusing on a group of acute
myeloid leukemia (AML) with very poor survival outcomes.
Our intentions are noble — put patients at the forefront of our myelodysplastic syndromes (MDS) and acute
myeloid leukemia (AML) investigations to
make their cure today's reality.
MD Anderson researchers recently
made an exciting new stride in the battle against acute
myeloid leukemia (AML).
His lab has
made contributions in the area of tumor induced immunosuppression of dendritic cells, characterization of human
myeloid derived suppressor cells, and the development of novel adjuvants for cancer vaccines.
20 - 30 % of patients with acute
myeloid leukemia have mutations of the FLT3 biomarker that
make them eligible for several FLT3 - targeted small molecule therapies currently in late stage clinical trials.